Edition:
United Kingdom

Nichi-Iko Pharmaceutical Co Ltd (4541.T)

4541.T on Tokyo Stock Exchange

1,187JPY
19 Aug 2019
Change (% chg)

¥12 (+1.02%)
Prev Close
¥1,175
Open
¥1,179
Day's High
¥1,189
Day's Low
¥1,175
Volume
219,500
Avg. Vol
279,245
52-wk High
¥1,907
52-wk Low
¥1,142

Latest Key Developments (Source: Significant Developments)

Nichi-Iko Pharmaceutical says application of International Financial Reporting Standards
Monday, 9 Apr 2018 

April 9 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japanese Generally Accepted Accounting Principles.IFRS effective from the annual report for fiscal year ended March 2018.  Full Article

Nichi-Iko Pharmaceutical says business and capital alliance with Eisai
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it forms business and capital alliance with Eisai Co Ltd <<<4523.T>>>.Says two entities will mainly cooperate on generic drug business model reform, ecosystem construction and API application .Says it will acquire 100 percent stake in ELMED EISAI Co Ltd from Eisai Co Ltd, for 17.12 billion yen in total.Says it plans to complete stake acquisition on April 1, 2019 .  Full Article

Nichi-Iko Pharmaceutical to start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29.  Full Article

Nichi-Iko Pharmaceutical says merger with wholly owned unit
Monday, 2 Oct 2017 

Oct 2(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it merged with a wholly owned unit, on Oct. 1.  Full Article

Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27 .* Says its unit, Yakuhan Pharmaceutical Co Ltd, received manufacturing and marketing approval for Infliximab BS for I.V. infusion 100 mg "AYUMI" .  Full Article